Lipid-lowering therapy for the primary prevention of coronary heart disease (Q33654065)

28 July 2017

1 reference

title

Lipid-lowering therapy for the primary prevention of coronary heart disease (English)

1 reference

28 July 2017

coronary artery disease

1 reference

Gotto AM Jr

1

1 reference

PubMed ID

10362217

28 July 2017

language of work or name

English

0 references

publication date

1 June 1999

1 reference

Journal of the American College of Cardiology

28 July 2017

1 reference

28 July 2017

33

1 reference

28 July 2017

7

1 reference

28 July 2017

2078-2082

1 reference

The primary prevention of myocardial infarction

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

The value of lowering cholesterol after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Cholesterol reduction yields clinical benefit. A new look at old data

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Report of the Conference on Low Blood Cholesterol: Mortality Associations

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Health policy on blood cholesterol. Time to change directions

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Serum cholesterol. Doing the right thing

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Prediction of Coronary Heart Disease Using Risk Factor Categories

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900114-X

7 January 2021

10.1016/S0735-1097(99)00114-X

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10362217